SABCS: Ribociclib Ups PFS in HR+ HER2− Advanced Breast Cancer

Share this content:
SABCS: Ribociclib Ups PFS in HR+ HER2− Advanced Breast Cancer
SABCS: Ribociclib Ups PFS in HR+ HER2− Advanced Breast Cancer

WEDNESDAY, Dec. 6, 2017 (HealthDay News) -- Ribociclib is beneficial for pre- and perimenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC), according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 5 to 9 in Texas.

Debu Tripathy, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues reported the results from a randomized phase III trial assessing ribociclib + tamoxifen/non-steroidal aromatase inhibitor and goserelin in pre- and peri-menopausal women. A total of 672 patients with HR+, HER2− ABC were randomized in a 1:1 ratio to ribociclib or placebo combined with tamoxifen or letrozole/anastrozole + goserelin.

The researchers found that progression-free survival (PFS) was significantly improved in the ribociclib versus the placebo arm (median PFS: 23.8 versus 13.0 months; hazard ratio, 0.553). Consistent PFS benefits were seen for ribociclib versus placebo in subgroup analyses. The overall response rate was 51 percent for ribociclib versus 36 percent for placebo, and clinical benefit rate was 80 versus 67 percent in patients with measurable disease at baseline.

"Longer follow-up is needed to determine whether the trial will meet its secondary end point of overall survival," Tripathy said in a statement. "However, these initial results are very exciting."

One author disclosed financial ties to Novartis, which manufactures ribociclib and funded the study.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Study Provides Estimates of U.S. Prevalence of Type 1, 2 Diabetes

Study Provides Estimates of U.S. Prevalence of Type ...

Prevalence of type 1 diabetes 0.5 percent, type 2 diabetes 8.5 percent among U.S. adults

Black Individuals at Highest Risk of Legal Intervention Injury

Black Individuals at Highest Risk of Legal Intervention ...

Increase in rates of injuries from 2005 to 2009, followed by a drop to 2015, returning to ~2005 levels

Research Links Doctor Burnout to Patient Safety Incidents

Research Links Doctor Burnout to Patient Safety Incidents

Physician burnout linked to increased risk of patient safety incidents, reduced patient satisfaction

is free, fast, and customized just for you!




Already a member?

Sign In Now »